COCHLEAR LIMITED (COH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

COH - COCHLEAR LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Cochlear is a medical device company that designs, manufactures and supplies hearing implants to the global market. Formed in 1981 with finance from the Australian government, it became a listed entity in 1995, and has grown to become the global leader in its field.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$245.34

30 Jul
2021

-2.300

OPEN

$244.00

-0.93%

HIGH

$247.78

95,022

LOW

$243.78

TARGET
$219.30 -10.6% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
ELX . PGC . AHZ . FPH . IPD . LHC . NAN . RMD . SOM . HLA . MX1 . CAT . VHT . ONE . IDX . PME . CSX . 4DX . BRN . EMV . UBI . LDX . RAP . RVA . MEB . IME . PCK . CMP . CYC . IMR . VTI . OVN . EYE . AT1 . CBL .
FNARENA'S MARKET CONSENSUS FORECASTS
COH: 1
Title FY19
Actual
FY20
Actual
FY21
Forecast
FY22
Forecast
EPS (cps) xxx - 399.6 377.4 xxx
DPS (cps) xxx 160.0 238.6 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 51.5% 49.1% xxx
PE Ratio xxx N/A 65.0 xxx
Dividend Yield xxx N/A 1.0% xxx
Div Pay Ratio(%) xxx N/A 63.2% xxx

Dividend yield today if purchased 3 years ago: 0.79%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.65

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 25/03 - 115c (0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2021 FactSet UK Limited. All rights reserved
Title 201520162017201820192020
EPS Basic xxxxxxxxxxxxxxx-399.6
DPS All xxxxxxxxxxxxxxx160.0
Sales/Revenue xxxxxxxxxxxxxxx1,352.3 M
Book Value Per Share xxxxxxxxxxxxxxx2,133.6
Net Operating Cash Flow xxxxxxxxxxxxxxx-157.8 M
Net Profit Margin xxxxxxxxxxxxxxx-17.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

This is work in progress. Bear with us. It'll be amazing.

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxxxxxx xx xxxxx-xxxxxx xxxx xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

25/06/2021

1

Outperform

$264.00

7.61%

After surveying 12 US-based audiologists with a specialisation in cochlear implants (CI), Macquarie highlights improved new CI patient numbers relative to pre-covid levels.

Cochlear was cited as best meeting key criteria for adult and paediatric patients and the highest rated overall product offering versus competitors. Participants expected the company to continue to increase share over the next 6-12 months.

The analyst retains an Outperform rating and the target rises to $264 from $245, in-line with forecast EPS changes and updates to the financial model parameters. 

FORECAST
Macquarie forecasts a full year FY21 dividend of 237.00 cents and EPS of 365.40 cents.
Macquarie forecasts a full year FY22 dividend of 343.00 cents and EPS of 489.50 cents.

Credit Suisse

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

COH STOCK CHART